FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587681330> ?p ?o ?g. }

• W2587681330 endingPage "1144" @default.
• W2587681330 startingPage "1144" @default.
• W2587681330 abstract "Abstract Immunomodulation following transfusion of cellular blood products presents as a generalized immunosuppression and/or production of alloantibody. The immunological effects of transfusion in immunocompetent subjects were evaluated in patients undergoing cardiac surgery with cardio-pulmonary by-pass. Subjects were consented for this IRB-approved study and were randomized to receive unmodified (STD) red blood cells (rbc), leukoreduced (LR) rbc or LR rbc that were g-irradiated (g-I). All platelet transfusions were collected LR and they were also g-I for the third arm. Patients were transfused only when clinically indicated. Subjects receiving no transfusions during the study served as a fourth control arm. Peripheral blood samples collected prior to surgery were controls for samples collected after surgery (day 10 +/- 4 and day 30 +/-5). HLA antibody production was evaluated in 245 subjects using single-antigen multiarray assays for antibody to both HLA class I and class II, a summary of results in shown in Table 1. For subjects with HLA antibody in their pre-surgery sample, these assays allowed evaluation of change in antibody specificity or levels. For these pre-sensitized subjects, there was no significant difference in HLA antibody production between the transfused study arms: even those not transfused showed an increase, most likely due to activation of memory responses. For subjects without HLA antibody in their pre-surgery sample, recipients of LR products showed little increase supporting prior studies showing the efficacy of LR in reducing antibody. However the protection afforded by LR was abrogated by g-I. This was an unexpected finding. We evaluated cellular and cytokine mediators of immunosuppression in the first 139 consecutive subjects of the 245 subjects enrolled in this study. This part of the study was powered for hypothesis generation, not statistical significance. Mononuclear cells (MNC) were isolated from each sample, frozen, and all samples from a subject assayed together. We assayed these cells for production of TGFB1 using ELISPOT. We used flow cytometry phenotyping for markers of CD4+25+ T regulatory cells (CTLA4, FoxP3) and for intracellular cytokines for CD4+ and CD4- NKT cells (IFNG, IL-4, IL-10). As shown in Table 2, recipients of standard rbc showed an increase (following transfusion and surgery) in TGFB1 producing mononuclear cells with a lower increase in recipients of LR rbc and those who were not transfused, but further reduced in the group receiving g-I LR products. Recipients of standard rbc or of LR rbc showed an increase of T lymphocytes expressing FoxP3 or CTLA4, and of CD4+ NKT cells producing IL-4. In contrast, subjects whose LR products were g-I showed a markedly lower increase in all three measures. These data identify an increase in mediators of immunosuppression in recipients of standard rbc and LR rbc that was reduced in recipients of g-I and LR rbc and platelets. Surgery and bypass alone increased the numbers of TGFB1+ MNC and IL4+ NKT cells suggesting a role for the innate immune system in immunosuppression following transfusion. This study is the first to exam the immunomodulatory effects of transfusion by combining measurement of immunosuppression in ex vivo surrogate assays and measurement of HLA antibody production inclusive of pre-sensitized subjects. Our observations of differences in responses to blood products prepared with g-I plus LR compared to LR alone were unexpected and require confirmation. It suggests that the reduction in immunosuppressive cells and cytokines in the recipients of g-I and LR products contributed to the increased allosensitization we observed in that arm compared to recipients of LR products. It may be possible to manipulate immunomodulation after transfusion to reach a desired goal for specific patient populations. Disclosures Slichter: Department of Defense: Research Funding; Terumo BCT: Research Funding; Cerus Corporation: Research Funding; Cellphire, Inc.: Research Funding; Genentech: Research Funding." @default.
• W2587681330 created "2017-02-17" @default.
• W2587681330 creator A5002544827 @default.
• W2587681330 creator A5039591169 @default.
• W2587681330 creator A5053497191 @default.
• W2587681330 creator A5079990651 @default.
• W2587681330 date "2015-12-03" @default.
• W2587681330 modified "2023-09-27" @default.
• W2587681330 title "Immunomodulatory Effects of Transfusion" @default.
• W2587681330 doi "https://doi.org/10.1182/blood.v126.23.1144.1144" @default.
• W2587681330 hasPublicationYear "2015" @default.
• W2587681330 type Work @default.
• W2587681330 sameAs 2587681330 @default.
• W2587681330 citedByCount "1" @default.
• W2587681330 countsByYear W25876813302017 @default.
• W2587681330 crossrefType "journal-article" @default.
• W2587681330 hasAuthorship W2587681330A5002544827 @default.
• W2587681330 hasAuthorship W2587681330A5039591169 @default.
• W2587681330 hasAuthorship W2587681330A5053497191 @default.
• W2587681330 hasAuthorship W2587681330A5079990651 @default.
• W2587681330 hasBestOaLocation W25876813301 @default.
• W2587681330 hasConcept C126322002 @default.
• W2587681330 hasConcept C141071460 @default.
• W2587681330 hasConcept C147483822 @default.
• W2587681330 hasConcept C159654299 @default.
• W2587681330 hasConcept C188280979 @default.
• W2587681330 hasConcept C203014093 @default.
• W2587681330 hasConcept C2778430493 @default.
• W2587681330 hasConcept C2780014101 @default.
• W2587681330 hasConcept C2780252810 @default.
• W2587681330 hasConcept C71924100 @default.
• W2587681330 hasConcept C89560881 @default.
• W2587681330 hasConcept C90924648 @default.
• W2587681330 hasConceptScore W2587681330C126322002 @default.
• W2587681330 hasConceptScore W2587681330C141071460 @default.
• W2587681330 hasConceptScore W2587681330C147483822 @default.
• W2587681330 hasConceptScore W2587681330C159654299 @default.
• W2587681330 hasConceptScore W2587681330C188280979 @default.
• W2587681330 hasConceptScore W2587681330C203014093 @default.
• W2587681330 hasConceptScore W2587681330C2778430493 @default.
• W2587681330 hasConceptScore W2587681330C2780014101 @default.
• W2587681330 hasConceptScore W2587681330C2780252810 @default.
• W2587681330 hasConceptScore W2587681330C71924100 @default.
• W2587681330 hasConceptScore W2587681330C89560881 @default.
• W2587681330 hasConceptScore W2587681330C90924648 @default.
• W2587681330 hasIssue "23" @default.
• W2587681330 hasLocation W25876813301 @default.
• W2587681330 hasOpenAccess W2587681330 @default.
• W2587681330 hasPrimaryLocation W25876813301 @default.
• W2587681330 hasRelatedWork W1970895673 @default.
• W2587681330 hasRelatedWork W1977392131 @default.
• W2587681330 hasRelatedWork W1992995409 @default.
• W2587681330 hasRelatedWork W1995924033 @default.
• W2587681330 hasRelatedWork W2019101100 @default.
• W2587681330 hasRelatedWork W2040191638 @default.
• W2587681330 hasRelatedWork W2040879941 @default.
• W2587681330 hasRelatedWork W2416501090 @default.
• W2587681330 hasRelatedWork W2903053854 @default.
• W2587681330 hasRelatedWork W4313351422 @default.
• W2587681330 hasVolume "126" @default.
• W2587681330 isParatext "false" @default.
• W2587681330 isRetracted "false" @default.
• W2587681330 magId "2587681330" @default.
• W2587681330 workType "article" @default.